Trials / Suspended
SuspendedNCT06963346
Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology Agents
HERO Trial: Phase I Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology Agents in Localized Bladder Cancer
- Status
- Suspended
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
In this study, we aim to evaluate the safety and efficacy of neoadjuvant combination using intravesical romidepsin and durvalumab in cisplatin-ineligible patients with muscle invasive bladder cancer (MIBC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Romidepsin | Administered as intravesical treatment. |
| DRUG | Durvalumab | Administered as intravenous treatment. |
Timeline
- Start date
- 2025-06-24
- Primary completion
- 2028-04-01
- Completion
- 2028-04-01
- First posted
- 2025-05-09
- Last updated
- 2026-03-09
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06963346. Inclusion in this directory is not an endorsement.